- Home
- JANX
as 08-15-2025 9:38am EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | 2021 |
| Target Price: | $90.63 | AVG Volume (30 days): | 892.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.97 - $71.71 | Next Earning Date: | 08-07-2025 |
| Revenue: | $439,000 | Revenue Growth: | -97.10% |
| Revenue Growth (this year): | -96.15% | Revenue Growth (next year): | 1470.83% |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target
Business Wire
3 months ago
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Business Wire
3 months ago
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Clinical Trials Arena
3 months ago
Janux commences Phase Ib studies in trial for prostate cancer treatment
Insider Monkey
3 months ago
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential
Business Wire
3 months ago
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
Insider Monkey
3 months ago
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
Insider Monkey
5 months ago
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.